Abstract: Provided herein is a synthetic complex comprising one or more human leukocyte antigens (synHLA), wherein said complex is inhibited from eliciting an immune response. Also provided are a nucleic acid molecule encoding said complex, an immune incompetent stem cell comprising said complex or said nucleic acid molecule, and a method of treating a disease or disorder comprising administering said complex, said nucleic acid molecule, or said immune incompetent stem cell to a subject in need thereof.

Abstract: The present disclosure provides methods, compounds, and systems for synthesizing a nucleic acid molecule. The methods may comprise spatially separating a set of barcoded oligonucleotides corresponding to a target nucleic acid molecule and performing a nucleic acid assembly using the oligonucleotides. A computer system coupled to a process control software program may be configured to apparatuses and configured to carry out the methods of the present disclosure.

Abstract: The invention relates to panels of biomarkers for diagnosing and/or monitoring the progression of an active mycobacterial infection or for diagnosing the absence of a mycobacterial infection, particularly tuberculosis. Such diagnosis and/or monitoring may be differential diagnosis between active tuberculosis patients and patients with latent, non-progressing tuberculosis or healthy or sick patients, irrespective of whether the patients have been characterised as being sputum smear positive or sputum smear negative, and/or irrespective of whether they have been characterised as being HIV positive or HIV negative. The above pertain in all aspects both to pulmonary and extra pulmonary Mycobacterium tuberculosis infections, with Mycobacterium tuberculosis being the causative organism in tuberculosis.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

Abstract: The disclosure provides a method of treatment of a B-cell lymphoma or leukemia, including diffuse large B-cell lymphoma (DLBCL) comprising a CD19-directed chimeric antigen receptor (CAR) genetically modified T-cell immunotherapy in combination with a 4-IBB (CD137) agonist. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T-cell therapy provided herein.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

Abstract: The invention relates to methods of treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of an inhibitor of the interaction between the PD-1 receptor and its ligand PD-L1.

Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.

Abstract: The present invention relates to the use of cluster of differentiation (CD) molecules in detecting the presence and progression of one or more disease states in an individual. In particular it relates to the use of profiles of shed CD (sCD) molecules in detecting and assessing the progression of one or more disease states in an individual. Further uses of sCD profiles according to the present invention are also described.

Abstract: This invention relates to methods of testing, diagnosing, monitoring, prognostically stratifying and classifying disease, disorders and other medical conditions and physiological states through the detection and analysis of soluble CD antigens in a body fluid sample.

Abstract: This invention relates to methods of testing, diagnosing, monitoring, prognostically stratifying and classifying disease, disorders and other medical conditions and physiological states through the detection and analysis of soluble CD antigens in a body fluid sample.

Abstract: This invention relates to methods of testing, diagnosing, monitoring, prognostically stratifying and classifying disease, disorders and other medical conditions and physiological states through the detection and analysis of soluble CD antigens in a body fluid sample.

Abstract: The present invention relates to the use of cluster of differentiation (CD) molecules in detecting the presence and progression of one or more disease states in an individual. In particular it relates to the use of profiles of shed CD (sCD) molecules in detecting an assessing the progress of one or more disease states in an individual. Further uses of sCD profiles according to the present invention are also described.

Abstract: The present invention relates to the use of cluster of differentiation (CD) molecules in detecting the presence and progression of one or more disease states in an individual. In particular it relates to the use of profiles of shed CD (sCD) molecules in detecting and assessing the progression of one or more disease states in an individual. Further uses of sCD profiles according to the present invention are also described.